Skip to main content

Locally Advanced Non-Small Cell Lung Cancer NRG-LU008

Status: Open to Enrollment
Email us to enroll

Study details

View study details on clinicaltrials.gov.

Locations

  • Sutter Health System Wide

Clinical trial FAQs

Information for patients and study volunteers, including frequently asked questions.

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-small Cell Lung Cancer

This phase III trial compares the effect of adding stereotactic body radiation therapy (SBRT) to the usual treatment (conventional image guided radiation therapy [IGRT] and chemotherapy followed by immunotherapy with durvalumab or osimertinib) versus the usual treatment alone in treating patients with non-small cell lung cancer that has spread to nearby tissue or lymph nodes (locally advanced) and cannot be treated by surgery (inoperable). 

Christopher U Jones, M.D., FACR
Christopher U Jones, M.D., FACR
Principal investigator
View profile

Related clinical trials

View all clinical trials
  • Clinical trial

    Adjuvant Early-stage Non-small Cell Lung Cancer Beamion LUNG-3

    Beamion LUNG-3: A Randomized, Controlled, Multi-center Trial Evaluating Zongertinib as an Adjuvant Monotherapy Compared With Standard of Care in Patients With Early-stage, Resectable Non-small Cell Lung Cancer (Stage II-IIIB) Harboring Tyrosine Kinase Domain Activating HER2 Mutations

    Status: Open to Enrollment

  • Clinical trial

    Adjuvant Monotherapy vs. Standard of Care Early-stage, Resectable Non-small Cell Lung Cancer

    Beamion LUNG-3: A Randomized, Controlled, Multi-center Trial Evaluating Zongertinib as an Adjuvant Monotherapy Compared With Standard of Care in Patients With Early-stage, Resectable Non-small Cell Lung Cancer (Stage II-IIIB) Harboring Tyrosine Kinase Domain Activating HER2 Mutations

    Status: Coming Soon

  • Clinical trial

    Adjuvant Non Small Lung Cancer TroFuse-019

    A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy Followed by Surgery (MK-2870-019) (TroFuse-019)

    Status: Open to Enrollment

  • Clinical trial

    Adjuvant Non-Small Cell Lung Cancer A081801

    Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO

    Status: Open to Enrollment

  • Clinical trial

    Adjuvant Non-Small-Cell Lung Cancer C5851005 PADL1NK-005

    PADL1NK-005: A Randomized, Phase 3, Open-Label Study to Evaluate PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

    Status: Open to Enrollment

You're leaving our site

The website you have selected is an external one located on another server. This website may contain links to third party sites. These links are provided for convenience purposes and are not under the control of Sutter Health. Do you wish to continue?